Clostridium butyricum inhibits epithelial–mesenchymal transition of intestinal carcinogenesis through downregulating METTL3
Cancer Science · 2023
DOI: 10.1111/cas.15839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Kexin Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, National Key Clinical Specialty, Tianjin Institute of Di…. Hauptthemen laut MEDLINE: Clostridium butyricum, Colorectal Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Science and Technology Pillar Program of Tianjin, Tianjin Key Medical Discipline (Specialty) Construction Project.
Abstract (Originalsprache)
Colorectal cancer (CRC) is related to gut microbiota dysbiosis, especially butyrate‐producing bacteria reduction. Our previous study suggested that administration of Clostridium butyricum , a butyrate‐producing bacterium, exerts a crucial effect against CRC, however the potential mechanism is not clear. We first found that methyltransferase‐like 3 (METTL3) showed a positive correlation with proliferation, epithelial–mesenchymal transition (EMT), DNA repair, metastasis, and invasion in a database analysis. The expression of METTL3 gradually increased from human normal colon tissue, to adenoma, and carcinoma, and was positively correlated with E‐cadherin and CD34 levels. Overexpression of METTL3 promoted the proliferation, migration, and invasion of CRC cells and induced vasculogenic mimicry (VM) formation. Clostridium butyricum could downregulate METTL3 expression in CRC cells and decrease the expression of vimentin and vascular endothelial growth factor receptor 2 to reduce EMT and VM formation. Clostridium butyricum alleviated the pro‐oncogenic effect of METTL3 overexpressing plasmid in CRC cells. The anti‐EMT effect on METTL3 reduction of C. butyricum could be blunted by knocking down G‐protein coupled receptor 43. Moreover, C. butyricum prevented EMT and VM and inhibited tumor metastasis in nude mice. Accordingly, C. butyricum could inhibit EMT and VM formation of intestinal carcinogenesis through downregulating METTL3. These findings broaden our understanding of probiotics supplement in CRC prevention and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, National Key Clinical Specialty, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianji…
ORCID-Profile: Hailong Cao
Förderung
- National Natural Science Foundation of China
- Key Project of Science and Technology Pillar Program of Tianjin
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Zhang, K., Dong, Y., Li, M., Zhang, W., Ding, Y., Wang, X., Chen, D., Liu, T., Wang, B., Cao, H., & Zhong, W. (2023). Clostridium butyricum inhibits epithelial–mesenchymal transition of intestinal carcinogenesis through downregulating METTL3. Cancer Science. https://doi.org/10.1111/cas.15839
Vancouver
Zhang K, Dong Y, Li M, Zhang W, Ding Y, Wang X, et al. Clostridium butyricum inhibits epithelial–mesenchymal transition of intestinal carcinogenesis through downregulating METTL3. Cancer Science. 2023. doi:10.1111/cas.15839
BibTeX
@article{Zhang2023,
author = {Zhang, Kexin and Dong, Yue and Li, Mengfan and Zhang, Wanru and Ding, Yiyun and Wang, Xin and Chen, Danfeng and Liu, Tianyu and Wang, Bangmao and Cao, Hailong and Zhong, Weilong},
title = {Clostridium butyricum inhibits epithelial–mesenchymal transition of intestinal carcinogenesis through downregulating METTL3},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15839}
}
EUVIMED